[go: up one dir, main page]

BRPI0518476A2 - compostos e derivados de dibenzil amina - Google Patents

compostos e derivados de dibenzil amina

Info

Publication number
BRPI0518476A2
BRPI0518476A2 BRPI0518476-2A BRPI0518476A BRPI0518476A2 BR PI0518476 A2 BRPI0518476 A2 BR PI0518476A2 BR PI0518476 A BRPI0518476 A BR PI0518476A BR PI0518476 A2 BRPI0518476 A2 BR PI0518476A2
Authority
BR
Brazil
Prior art keywords
derivatives
cholesterol
amine compounds
compounds
levels
Prior art date
Application number
BRPI0518476-2A
Other languages
English (en)
Inventor
George Chang
Mary Theresa Didiuk
Peter Hans Dorff
Ravi Shanker Garigipati
Wenhua Jiao
Bruce Allen Lefker
David Austen Perry
Roger Benjamin Ruggeri
Toby James Underwood
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of BRPI0518476A2 publication Critical patent/BRPI0518476A2/pt

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D257/00Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms
    • C07D257/02Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D257/04Five-membered rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/06Antihyperlipidemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/04Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D231/00Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D257/00Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms
    • C07D257/02Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D257/04Five-membered rings
    • C07D257/06Five-membered rings with nitrogen atoms directly attached to the ring carbon atom
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

COMPOSTOS E DERIVADOS DE DIBENZIL AMINA. Compostos e derivados de dibenzil amina, composições farmacêuticas contendo tais compostos e o uso de tais compostos para elevar certos níveis de lipidio no plasma, incluindo lípoproteina de alta densidade-colesterol e para reduzir outros níveis de lipídio no plasma, tais como LDL- colesterol e triglicerideos e, por conseguinte, tratar doenças que são exacerbadas por baixos níveis de HDL-colesterol e/ou altos níveis de LDL-colesterol e triglicerídeos, tais como aterosclerose e doenças cardiovasculares em alguns mamíferos, incluindo humanos.
BRPI0518476-2A 2004-11-23 2005-11-21 compostos e derivados de dibenzil amina BRPI0518476A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US63043404P 2004-11-23 2004-11-23
US71561705P 2005-09-12 2005-09-12
PCT/IB2005/003500 WO2006056854A1 (en) 2004-11-23 2005-11-21 Dibenzyl amine compounds and derivatives

Publications (1)

Publication Number Publication Date
BRPI0518476A2 true BRPI0518476A2 (pt) 2008-11-18

Family

ID=35828305

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0518476-2A BRPI0518476A2 (pt) 2004-11-23 2005-11-21 compostos e derivados de dibenzil amina

Country Status (22)

Country Link
US (1) US20090239865A1 (pt)
EP (1) EP1817297A1 (pt)
JP (1) JP2008520645A (pt)
KR (1) KR20070069213A (pt)
AP (1) AP2007003980A0 (pt)
AR (1) AR053784A1 (pt)
AU (1) AU2005308584A1 (pt)
BR (1) BRPI0518476A2 (pt)
CA (1) CA2589322A1 (pt)
CR (1) CR9089A (pt)
EA (1) EA200700924A1 (pt)
GT (1) GT200500339A (pt)
IL (1) IL183133A0 (pt)
MA (1) MA29039B1 (pt)
MX (1) MX2007006137A (pt)
NL (1) NL1030486C2 (pt)
NO (1) NO20073025L (pt)
PE (1) PE20061124A1 (pt)
TN (1) TNSN07200A1 (pt)
TW (1) TW200630350A (pt)
UY (1) UY29222A1 (pt)
WO (1) WO2006056854A1 (pt)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1848430B1 (en) 2004-12-31 2017-08-02 Dr. Reddy's Laboratories Ltd. Novel benzylamine derivatives as cetp inhibitors
US8604055B2 (en) 2004-12-31 2013-12-10 Dr. Reddy's Laboratories Ltd. Substituted benzylamino quinolines as cholesterol ester-transfer protein inhibitors
CA2624032A1 (en) * 2005-09-30 2007-04-12 Merck & Co., Inc. Cholesteryl ester transfer protein inhibitors
CA2642130C (en) * 2005-12-28 2013-04-02 Reddy Us Therapeutics, Inc. Selective benzylamine derivatives and their utility as cholesterol ester-transfer protein inhibitors
RU2008130922A (ru) * 2005-12-29 2010-02-10 Новартис АГ (CH) Производные пиридиниламина в качестве ингибиторов белка-переносчика эфиров холестерина
UY30117A1 (es) * 2006-01-31 2007-06-29 Tanabe Seiyaku Co Compuesto amina trisustituido
PE20071025A1 (es) * 2006-01-31 2007-10-17 Mitsubishi Tanabe Pharma Corp Compuesto amina trisustituido
US8383660B2 (en) * 2006-03-10 2013-02-26 Pfizer Inc. Dibenzyl amine compounds and derivatives
US7919506B2 (en) 2006-03-10 2011-04-05 Pfizer Inc. Dibenzyl amine compounds and derivatives
US8232403B2 (en) 2006-05-10 2012-07-31 Novartis Ag Bicyclic derivatives as CETP inhibitors
JP2009536609A (ja) * 2006-05-11 2009-10-15 ノバルティス アクチエンゲゼルシャフト Cetp阻害剤としてのベンジルアミン誘導体
US7750019B2 (en) 2006-08-11 2010-07-06 Kowa Company, Ltd. Pyrimidine compound having benzyl(pyridylmethyl)amine structure and medicament comprising the same
US7790737B2 (en) 2007-03-13 2010-09-07 Kowa Company, Ltd. Substituted pyrimidine compounds and their utility as CETP inhibitors
CN101679309B (zh) * 2007-04-13 2012-02-29 兴和株式会社 具有二苄胺结构的新型嘧啶化合物和含有该化合物的药物
JP4834699B2 (ja) * 2007-07-30 2011-12-14 田辺三菱製薬株式会社 医薬組成物
JP4846769B2 (ja) * 2007-07-30 2011-12-28 田辺三菱製薬株式会社 医薬組成物
CA2722582A1 (en) * 2007-11-21 2009-05-28 Decode Genetics Ehf. Biaryl pde4 inhibitors for treating inflammation
CN102026970B (zh) * 2007-11-21 2013-07-31 解码遗传Ehf公司 用于治疗肺部和心血管病症的联芳基pde4抑制剂
GB2460597B8 (en) * 2008-02-01 2014-03-12 Amira Pharmaceuticals Inc N,N-disubstituted aminoalkylbiphenyl antagonists of prostaglandin D2 receptors
CN101952244B (zh) * 2008-02-01 2014-11-05 潘米拉制药公司 前列腺素d2受体的n,n-二取代氨基烷基联苯拮抗剂
JP2011512359A (ja) 2008-02-14 2011-04-21 アミラ ファーマシューティカルズ,インク. プロスタグランジンd2受容体のアンタゴニストとしての環式ジアリールエーテル化合物
WO2009108720A2 (en) 2008-02-25 2009-09-03 Amira Pharmaceuticals, Inc. Antagonists of prostaglandin d2 receptors
JP2011518130A (ja) 2008-04-02 2011-06-23 アミラ ファーマシューティカルズ,インク. プロスタグランジンd2受容体のアミノアルキルフェニルアンタゴニスト
GB2463788B (en) 2008-09-29 2010-12-15 Amira Pharmaceuticals Inc Heteroaryl antagonists of prostaglandin D2 receptors
US8378107B2 (en) 2008-10-01 2013-02-19 Panmira Pharmaceuticals, Llc Heteroaryl antagonists of prostaglandin D2 receptors
WO2010042652A2 (en) 2008-10-08 2010-04-15 Amira Pharmaceuticals, Inc. Heteroalkyl biphenyl antagonists of prostaglandin d2 receptors
WO2010057118A2 (en) 2008-11-17 2010-05-20 Amira Pharmaceuticals, Inc. Heterocyclic antagonists of prostaglandin d2 receptors
WO2010059838A2 (en) * 2008-11-20 2010-05-27 Decode Genetics Ehf Pde4 inhibitors selective for the long form of pde4 for treating inflammation and avoiding side effects
MX2012001542A (es) 2009-08-05 2012-06-19 Panmira Pharmaceuticals Llc Antagonista dp2 y usos del mismo.
CN102812000A (zh) 2010-01-06 2012-12-05 潘米拉制药公司 Dp2拮抗剂及其用途
JP2013538215A (ja) 2010-08-31 2013-10-10 エスエヌユー アールアンドディービー ファウンデーション PPARδアゴニストの胎児再プログラミング用途
KR20190025737A (ko) 2011-07-08 2019-03-11 노파르티스 아게 높은 트리글리세리드 대상체에서의 아테롬성동맥경화증의 치료 방법
KR101774223B1 (ko) * 2011-08-18 2017-09-12 닥터 레디스 레보러터리즈 리미티드 콜레스테릴 에스테르-전달 단백질(cetp) 억제제인 치환된 헤테로시클릭 아민 화합물
KR101803866B1 (ko) 2011-09-27 2017-12-04 닥터 레디스 레보러터리즈 리미티드 동맥경화증 치료에 유용한 콜레스테릴 에스테르-전달 단백질(cetp) 억제제로서 5-벤질아미노메틸-6-아미노피라졸로[3,4-b]피리딘 유도체
EP2934518B1 (en) 2012-12-19 2020-02-19 Merck Sharp & Dohme Corp. Spirocyclic cetp inhibitors
HUE057970T2 (hu) 2018-03-08 2022-06-28 Incyte Corp Aminopirazindiol-vegyületek mint PI3K-Y inhibitorok
US11046658B2 (en) 2018-07-02 2021-06-29 Incyte Corporation Aminopyrazine derivatives as PI3K-γ inhibitors
CN115677572B (zh) * 2021-07-29 2024-05-28 武汉思瓴生物科技有限公司 氟代酰胺类衍生物、药物组合物及其应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1360172A1 (en) * 2001-02-15 2003-11-12 Pfizer Products Inc. Ppar agonists
JP2003221376A (ja) * 2001-11-21 2003-08-05 Japan Tobacco Inc Cetp活性阻害剤
US6653334B1 (en) * 2002-12-27 2003-11-25 Kowa Co., Ltd. Benzoxazole compound and pharmaceutical composition containing the same
AU2005233160B2 (en) * 2004-04-13 2011-06-02 Merck Sharp & Dohme Corp. CETP inhibitors

Also Published As

Publication number Publication date
TW200630350A (en) 2006-09-01
KR20070069213A (ko) 2007-07-02
GT200500339A (es) 2006-06-22
NL1030486A1 (nl) 2006-05-24
AP2007003980A0 (en) 2007-06-30
WO2006056854A1 (en) 2006-06-01
US20090239865A1 (en) 2009-09-24
TNSN07200A1 (fr) 2008-11-21
EA200700924A1 (ru) 2007-10-26
IL183133A0 (en) 2007-09-20
MX2007006137A (es) 2007-07-19
NL1030486C2 (nl) 2006-10-24
UY29222A1 (es) 2006-06-30
AR053784A1 (es) 2007-05-23
NO20073025L (no) 2007-08-20
CA2589322A1 (en) 2006-06-01
JP2008520645A (ja) 2008-06-19
CR9089A (es) 2007-05-30
PE20061124A1 (es) 2006-10-13
MA29039B1 (fr) 2007-11-01
AU2005308584A1 (en) 2006-06-01
EP1817297A1 (en) 2007-08-15

Similar Documents

Publication Publication Date Title
BRPI0518476A2 (pt) compostos e derivados de dibenzil amina
BRPI0408897A (pt) derivados de 1,2,3,4-tetrahidro-e 1,2-dihidro-quinolina 1,2,4-substituìdos como inibidores de cetp para o tratamento de arteroesclerose e obesidade
TW200736235A (en) Dibenzyl amine compounds and derivatives
BR0316521A (pt) Ativadores de ppar
BR0207285A (pt) Agonistas de ppar
BRPI0410479A (pt) derivados de tetraidroisoquinolina como ativadores do ppar-(alfa)
AP2002002427A0 (en) Ppar compounds.
TNSN08178A1 (en) Triazolopyridine derivatives as inhibitors of lipases and phospholipases
BRPI0512624A (pt) compostos heteroarila e fenilsulfamoìla substituìdos
ECSP077333A (es) Compuestos de 4-amino-sustituido-2-sustituido-1,2,3,4-tetrahidroquinolina
TW200738652A (en) Dibenzyl amine compounds and derivatives
BRPI0607839A2 (pt) compostos 1,1,1-triflúor-3-[(benzil)-(pirimidin-2-il)-amino]-propan- 2-ol substituìdos
UY29124A1 (es) Compuestos de quinolina
UY29123A1 (es) Compuestos de 4-amino-sustituido-2-sustituido-1,2,3,4-tetrahidroquinolina
DOP2005000182A (es) Compuestos de 4-amino-sustituido-2-sustituido-1,2,3-tetrahidroquinolina
ECSP088730A (es) Derivados de dibencilamina como inhibidores de cetp
DOP2005000238A (es) Compuestos y derivados de dibencil amina
DOP2004000863A (es) Compuestos de quinolina y quinoxalina
CU20080164A7 (es) Compuestos y derivados de dibencilamina
DOP2005000179A (es) Compuesto de quinolina
DOP2003000762A (es) Activadores de ppar
ECSP993136A (es) 4- carboxiamino- 2- metil- 1,2,3,4- tetrahidroquinolinas

Legal Events

Date Code Title Description
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B11Y Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette]